These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 8114529)

  • 1. [Toxicology animal studies necessary for clinical research and registration of drugs for human use: conclusions of the International Harmonization Conference (I)].
    Rubio Terrés C; Duque I; Tristán C; Galende I
    Med Clin (Barc); 1993 Nov; 101(18):705-16. PubMed ID: 8114529
    [No Abstract]   [Full Text] [Related]  

  • 2. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopharmaceutical studies, a key to better toxicology.
    Zbinden G
    Xenobiotica; 1988 Jan; 18 Suppl 1():9-14. PubMed ID: 3344592
    [No Abstract]   [Full Text] [Related]  

  • 4. Preclinical testing for teratogenicity and developmental toxicity: methods and limitations.
    Barrow PC
    Therapie; 2002; 57(2):109-14. PubMed ID: 12185956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
    Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
    Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing.
    Weingand K; Brown G; Hall R; Davies D; Gossett K; Neptun D; Waner T; Matsuzawa T; Salemink P; Froelke W; Provost JP; Dal Negro G; Batchelor J; Nomura M; Groetsch H; Boink A; Kimball J; Woodman D; York M; Fabianson-Johnson E; Lupart M; Melloni E
    Fundam Appl Toxicol; 1996 Feb; 29(2):198-201. PubMed ID: 8742316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Animal toxicology studies necessary for clinical research and the registry of drugs for human use: conclusions of the International Conference of Harmonization (and II)].
    Tristán C; Galende I; Rubio Terrés C; Duque I
    Med Clin (Barc); 1994 May; 102(20):791-6. PubMed ID: 7913735
    [No Abstract]   [Full Text] [Related]  

  • 9. Toxicology in the drug discovery and development process.
    Dorato MA; Buckley LA
    Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune function tests for hazard identification: a paradigm shift in drug development.
    Gore ER
    Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):331-5. PubMed ID: 16623854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and kinetic aspects of toxicological studies. 19 May 1987, Paris, France.
    Xenobiotica; 1988 Jan; 18 Suppl 1():1-96. PubMed ID: 3344587
    [No Abstract]   [Full Text] [Related]  

  • 12. International Cooperation on Harmonisation of Technical Requirements for Approval of Veterinary Medicinal Products (VICH); final guidance for industry on "studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing" (VICH GL23); availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jan; 67(3):602-3. PubMed ID: 12358039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals.
    Van Deun K; Van Cauteren H; Vandenberghe J; Canning M; Vanparys P; Coussement W
    Adverse Drug React Toxicol Rev; 1997 Nov; 16(4):215-33. PubMed ID: 9608857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug research and its international harmonization].
    Idänpään-Heikkilä JE
    Duodecim; 1998; 114(10):951, 953-4. PubMed ID: 11524783
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of recommendations from the International Conference on Harmonization (ICH) for the safety evaluation of new medicines involving animal studies for the pharmaceutical industry.
    Scales MD
    Adverse Drug React Toxicol Rev; 1992; 11(1):5-12. PubMed ID: 1606283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug metabolism: an industrial research view of the future.
    Ober RE
    Drug Metab Rev; 1979; 10(2):315-9. PubMed ID: 551917
    [No Abstract]   [Full Text] [Related]  

  • 19. The inspection of drug metabolism and pharmacokinetic studies.
    Dent NJ
    Qual Assur; 1992 Jun; 1(3):230-6. PubMed ID: 1344678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproductive toxicology guidelines: comparison and application.
    Beltrame D; Mazué G
    Ann Ist Super Sanita; 1993; 29(1):3-14. PubMed ID: 8129269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.